The TD Cowen Insight Myostatin and/or activin inhibitors could tap into the significant obesity market with increased quality of weight loss to improve metabolic outcomes and decrease bone density loss
Tundidor D, Meek CL, Yamamoto J et al (2021) Continuous glucose monitoring time-in-range and HbA1c targets in pregnant women with type 1 diabetes
Another novel development is the use of research ligands for cosmetic rather than strictly recreational purposes, such as grey-market internet sales of the non-approved alpha-melanocyte-stimulating hormone tanning drugs known as melanotan peptides
Lau J, Bloch P, Schffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T